Clinical trials: Multiple Myeloma, completed
Leukemia, Multiple Myeloma
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
This study will use genomics-based technology, such as DNA microarrays, to more precisely diagnose subsets of lymphoma, leukemia and multiple myeloma patients.
- Conditions
- Leukemia, Multiple Myeloma, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- NCT00339963
- Where
- United States
- Volunteers
- 1,340 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Multiple Myeloma
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma…
- Trial name
- NCT05376345
- Testing
- LCAR-BCDR cells product
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Changzheng Hospital
Plasma Cell Leukemia, Recurrent Multiple Myeloma
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or plasma cell leukemia that has come back or…
- Conditions
- Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT03389347
- Testing
- Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Multiple Myeloma
Imaging Young Myeloma (IMAgerie JEune Myélome)
Multicenter open-label prospective comparative study of PET-scan and MRI at the time of diagnosis, after 3 cycles of induction therapy (RVD) and at the completion of therapy.
- Trial name
- IMAJEM (NCT01309334)
- Testing
- PET scan, MRI
- Where
- 17 sites in France
- Volunteers
- 152 people
- Sponsor
- Nantes University Hospital
Newly Diagnosed Multiple Myeloma
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
This is a phase II, multicenter, open-label study to evaluate the safety and efficacy of MLN9708 in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma.
- Trial name
- IFM2013-06 (NCT01936532)
- Testing
- MLN9708, Lenalidomide, Dexamethasone
- Where
- 10 sites in France
- Volunteers
- 42 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
Acute Leukemia, Multiple Myeloma
Study of 3D189 in Patients With Hematologic Malignancies
To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.
- Conditions
- Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome
- Trial name
- NCT05320809
- Testing
- 3D189
- Where
- 4 sites in China
- Volunteers
- 16 people
- Sponsor
- 3D Medicines
Multiple Myeloma
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.
- Trial name
- NCT05900882
- Testing
- Selinexor, Bortezomib, Lenalidomide
- Where
- 6 sites in China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
- Trial name
- NCT04151667
- Testing
- Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma
This study evaluated an individualized, nurse-delivered education program for managing treatment-related symptoms in patients with newly diagnosed multiple myeloma receiving bortezomib for the first time.
- Trial name
- NCT07774988
- Testing
- Individualized Nurse-Delivered Education Program
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Can Lafci
Multiple Myeloma
Precision Medicine Study
This will be a 2 year study to evaluate and improve cancer sequencing as applied to the characterization of tumor molecular make-up and the identification of novel therapeutics (total n=100; approximately 50/year).
- Trial name
- NCT06338150
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Advanced Cancer, Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced…
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT04354246
- Testing
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy.
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Compugen Ltd
Relapsed or Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- BENCH (NCT04939142)
- Testing
- SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
- Where
- 33 sites in China
- Volunteers
- 154 people
- Sponsor
- Antengene Corporation
Multiple Myeloma
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation
Hematopoietic reconstitution defined by a neutrophils number > 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number > 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without…
- Trial name
- Expansion (NCT00461955)
- Testing
- autologous peripheral blood stem cell transplantation, ex vivo amplified
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Plasma Cell Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression…
- Trial name
- IONA-MM (NCT04458831)
- Testing
- isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 129 sites in United States, Argentina and 19 more
- Volunteers
- 583 people
- Sponsor
- Sanofi
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma Bone Lesions, Multiple Myeloma (MM)
Rehabilitation Management for Patients With Multiple Myeloma
Multiple myeloma (MM) is the second most common blood cancer. Bone involvement is very common in these patients: it is estimated that between 80% and 90% will develop bone lesions during the course of the disease.
- Trial name
- FKTMM2022 (NCT06838065)
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Relapse Multiple Myeloma, Refractory Multiple Myeloma
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
Multiple myeloma (MM) is a type of cancer of the white blood cells, called plasma cells. These plasma cells help in fighting infections.
- Trial name
- MUST (NCT05742217)
- Where
- 20 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Pfizer
Multiple Myeloma, Light Chain Nephropathy
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus…
- Conditions
- Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
- Trial name
- NCT06483139
- Testing
- Plasma exchange, Daratumumab
- Where
- United States
- Volunteers
- 549 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Relapsed/Refractory Multiple Myeloma
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or…
- Trial name
- NCT07689006
- Testing
- Pomalidomide-containing regimens, Non-pomalidomide-containing regimens
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- Bristol-Myers Squibb